Nasdaq GlobeNewswire

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)

Del

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million.

The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidelity International. Fidelity International is a cornerstone investor in the IPO and will hold approximately 10% of the issued capital of the Company upon completion of the IPO.

Telix is Chaired by ex-Macquarie Bank Chairman Mr. Kevin McCann AM. The Board of Directors consists of Caledonia Investments co-founder Dr. Mark Nelson (Non-executive Director) and Mr. Oliver Buck (Non-executive Director), co-founder and member of the Supervisory Board of ITM Group, a global leader in the production of medical isotopes. Co-founder and Chief Medical Officer Dr. Andreas Kluge, and Co-Founder and CEO Christian Behrenbruch are appointed as Executive Directors.

Dr. Behrenbruch commented, "With our portfolio of highly-promising clinical programs in renal, prostate and brain (glioblastoma) cancer, Telix is uniquely positioned for global leadership in the fast-growing field of MTR. We have excellent patient data underpinning our development programs, a highly experienced clinical development team and meaningful partnerships with thought leaders in the field. This financing will enable the company to reach several major development and commercial milestones over the next 24 months."

The offer of new fully paid ordinary shares by Telix Pharmaceuticals is made under a prospectus lodged with the Australian Securities and Investments Commission (ASIC) on 16 October 2017. The Offer comprises a Retail Offer and an Institutional Offer.

Australian-resident retail investors are eligible to apply for shares under the Retail Offer via the Offer website at www.telixpharma.com/IPO.

The Offer is expected to close on or around 8 November 2017 and Telix is expected to commence trading on ASX on 15 November 2017, under the ticker "TLX". The prospectus is available to Australian-resident investors via the Telix website at www.telixpharma.com/IPO.

For further information about the IPO, please contact:

Offer Information Line  : 1800 262 299 (within Australia) or +61 1800 262 299 (outside Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday during the Offer Period 
 
 Corporate Contact: 

 Dr. Christian Behrenbruch
 CEO 
 Telix Pharmaceuticals Limited
 Email: chris@telixpharma.com
 Investor and Media Relations:  

 Kyahn Williamson
 Head of Investor Relations
 WE Buchan 
 Email: kwilliamson@buchanwe.com.au


For further information about Telix Pharmaceuticals Limited and the IPO, please refer to the prospectus. Potential investors should carefully consider the prospectus and investment risk factors before deciding whether to acquire shares. Please note that the offer of shares under the IPO will be made in, or accompanied by, a copy of the prospectus and anyone who wants to acquire Telix shares under the IPO will need to complete an application form that will be in or will accompany the prospectus.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

SEMAFO Mourns Passing of Board Chairman Jean Lamarre23.11.2017 22:01Pressemelding

MONTREAL, Nov. 23, 2017 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF) (OMX:SMF) announces with sadness the passing of Mr. Jean Lamarre, Chairman of the Board of Directors of the Corporation, on November 22, 2017 following a short illness. Mr. Lamarre joined the Corporation's Board of Directors in 1997 and was appointed Chairman of the Board in 2000, a position he held until his demise. "Jean made an indelible mark on SEMAFO, both in terms of his corporate governance expertise and his 45 years of experience in Africa," said President and CEO Benoit Desormeaux. "Over his 20-year tenure with SEMAFO, he brought unique insight, business acumen and leadership to the Corporation as it transitioned from an exploration company to a junior gold producer. He did this, always without compromising his values: the integrity of the Corporation, his deep love for Africa and its people, and his priority to SEMAFO's long-term sustainability. On behalf of SEMAFO's Board of Directors, management and employe

Premier to join industry leaders at BDA London forum23.11.2017 21:39Pressemelding

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Premier David Burt will join more than two-dozen Bermuda executives in a multi-industry forum being held in London next week to showcase the breadth of expertise and advantages offered by the island's global business market. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/78c5ac53-07f7-4dd8-83e0-753ea5b4c80b Organised by the Bermuda Business Development Agency (BDA), the one-day event Tuesday, November 28 at ME London has attracted over 200 registrants. It will feature top regulatory and industry leaders in moderated discussion panels covering re/insurance, captive insurance, insurance-linked securities, asset management, family offices, and trust and private-client business. A networking reception will wrap the event in the evening. "The government supports the Bermuda Business Development Agency in this awareness-raising event that offers such gre

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00Pressemelding

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement

Euroloan Opens New Market in Spain23.11.2017 11:10Pressemelding

Helsinki, Finland, 2017-11-23 11:10 CET (GLOBE NEWSWIRE) -- According to James Hickson, CEO of Euroloan Group, initiating services in the Spanish market is a key step in the expansion strategy of the Fintech group. “We have seen a growing demand for easy payment solutions in several markets, and the Spanish market in particular offers a massive opportunity for growth with Euroloan’s advanced payment and credit solutions. Merchants and Consumers appreciate our simple, fast and efficient services. It’s all about making their life easier. Consistent with our strategy, we have identified a number of partners to accelerate our market entry approach and expect to be providing our lending and merchant solutions by the end of the 1Q 2018” The Group is now present in five countries in Europe, including Finland, Sweden, Poland, Luxembourg and Spain. “Euroloan aims to open up several additional new markets”, says Tommi Lindfors, Chairman of the Board of Euroloan Group. “Spain is an importan

BDA partners with government to attract cryptocurrency23.11.2017 06:25Pressemelding

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- The Bermuda Business Development Agency (BDA) will take a lead role in an initiative launched by the Bermuda government today to accelerate the establishment and growth of digital currency business on the island. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/457f43b9-d7bb-48f1-83e2-b856b33ebacc At a press conference held by Premier the Hon David Burt and National Security Minister the Hon Wayne Caines, the government announced the formation of a task force comprising two teams to advance Bermuda's regulatory environment as a destination for utility tokens, tokenised securities, cryptocurrencies, and coin offerings. BDA Consultant for Emerging Technologies John Narraway was named as chair of the Blockchain Business Development Working Group, while BDA Board member Lydia Dickens will chair the Blockchain Legal and Regulatory Working Group, of which

VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39Pressemelding

The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes.  The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom